Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial (Q34539049)

2 August 2017

title

Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial (English)

1 reference

Arjan A van de Loosdrecht

2 August 2017

main subject

phase II clinical trial

0 references

systemic mastocytosis

1 reference

1 reference

5

object named as

Arjan A van de Loosdrecht

1 reference

2 August 2017

Helga J Droogendijk

1

1 reference

2 August 2017

Hanneke J C Kluin-Nelemans

2

1 reference

2 August 2017

Jaap J van Doormaal

3

1 reference

2 August 2017

Arnold P Oranje

4

1 reference

2 August 2017

Paul L A van Daele

6

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

2 August 2017

1 reference

2 August 2017

volume

107

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

345-351

1 reference

2 August 2017

cites work

Systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.21996

1 reference

7 January 2021

Diagnostic criteria and classification of mastocytosis: a consensus proposal

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Response to interferon alfa-2b in a patient with systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Response of severe systemic mastocytosis to interferon alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Cladribine therapy for systemic mastocytosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Treatment of systemic mast-cell disease with cladribine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Treatment of systemic mast cell disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Treatment of mastocytosis: pharmacologic basis and current concepts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Mastocytosis: molecular mechanisms and clinical disease heterogeneity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Imatinib for systemic mast-cell disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Clinical scoring of cutaneous mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21996

7 January 2021

Identifiers

DOI

10.1002/CNCR.21996

1 reference

2 August 2017

1 reference